Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mutant carp parvalbumin
- Development stage
- Phase 2
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Mutant carp parvalbumin (mCyp c 1) is a hypoallergenic recombinant protein developed for allergen-specific immunotherapy of fish allergy. It is a modified version of the wild-type carp parvalbumin (Cyp c 1), engineered to have significantly reduced allergenicity while maintaining immunogenicity. The protein is administered subcutaneously as an alum-adsorbed formulation.
- Brand names
- FAST-fish mCyp c 1
- Other names
- rCyp c 1mut
02
Targets
IgE-anti-parvalbumin (Human immunoglobulin E specific for fish parvalbumin)
Beyond the preview
Go deeper on mutant carp parvalbumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mutant carp parvalbumin.